GlassScriptPhysician profile
Abdul Kareem Jaffer
NPI 1225025422
$1,896.50
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $258 · 2021: $302 · 2022: $348 · 2023: $199 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322 · Education: $0.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.67 |
| Education | $0.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $738.05 | 2019-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $305.07 | 2019-2024 | Ultomiris |
| Ucb, INC. | $93.01 | 2019-2024 | Rystiggo |
| Sunovion Pharmaceuticals INC. | $88.46 | 2019-2021 | |
| Endogastric Solutions, INC | $85.67 | 2019 | |
| Neurocrine Biosciences, INC. | $82.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.60 | 2019-2023 | Ponvory |
| Biogen, INC. | $57.30 | 2019-2022 | |
| Eisai INC. | $50.44 | 2020-2021 | |
| Abbvie INC. | $48.97 | 2023 | |
| Scilex Pharmaceuticals INC. | $42.43 | 2019 | |
| Lilly USA, LLC | $32.86 | 2019 | |
| Livanova USA, INC. | $27.45 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.60 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $21.65 | 2024 | Nuedexta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $18.49 | 2019 | |
| Acadia Pharmaceuticals INC | $18.11 | 2022 | |
| Lundbeck LLC | $17.70 | 2019 | |
| Medtronic Minimed, INC. | $17.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.52 | 2021 | |
| Genzyme Corporation | $15.52 | 2022 | |
| Emd Serono, INC. | $13.43 | 2023 | Mavenclad |
| Neurelis, INC. | $11.71 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Jaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.